You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The updated elPrep 5 sequencing processing platform is said to run 8 to 16 times faster than GATK while producing similar results, thanks to parallel computing and new algorithms.
The funding will help the San Francisco-based firm apply low-depth NGS as it builds diagnostic tests to aid therapy selection in more diverse populations.
Genomic data analytics firm Sentieon uses the challenges to prove and increase customer confidence in its bioinformatics technology.
The software generates reports for pharmacogenomics, rare diseases, predispositions to common diseases, and nutrigenomics.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
The firms are developing clinical and RUO workflows that use NGS for pathogen identification and will comarket IDbyDNA's Explify data platform.
The deal gives Definitive Healthcare a foothold in the genomics market as it looks to build its own genomic data pipeline to serve through PatientFinder's CohortBuilder tool.
The exclusive distribution deal expands the Finnish bioinformatics software company's footprint in the Middle East, Africa, and Asia.
Medley Genomics' software, called HotNet2, assesses tumor genomic heterogeneity from large-scale sequencing datasets across patient cohorts.
The acquisition, slated to close in the coming days, will give Invitae access to Clear Genetics' chatbot Gia, or Genetic Information Assistant.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.